Within our retrospective LCM cohort, 70% of patients showed significantly increased expression of CDKN2A (a proxy marker for HPV infection) in regions of carcinoma in situ relative to normal epithelium. The gene discussed is CDKN2A; the disease is in situ carcinoma.